The Daily Biotech Pulse: NRx’s Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours.
Syros Pharmaceuticals Q3 EPS $(0.41) Beats $(0.44) Estimate, Sales $5.70M Beat $4.49M Estimate
Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.44) by 6.82 percent. This is a 4.65 percent increase over losses of $(0.43) per share
Earnings Scheduled For November 5, 2021
Companies Reporting Before The Bell
• Brookfield Renewable (NYSE:BEPC) is projected to report earnings for its third quarter.
Earnings Preview For Syros Pharmaceuticals
Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Friday, 2021-11-05. Here's what investors need to know before the announcement.
Analysts estimate that Syros Pharmaceuticals will likely report an Earnings Per Share (EPS) of $-0.44
Syros Pharmaceuticals Names Jason Haas As CFO
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25
Roth Capital Maintains Buy on Syros Pharmaceuticals, Raises Price Target to $23
Roth Capital analyst Zegbeh Jallah maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and raises the price target from $20 to $23.
Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings
Syros Pharmaceuticals Inc (NASDAQ:SYRS) announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609. Updated data…
Syros Pharma Highlights Presentation Of New Data From Phase 1 Trial Of SY-5609
Updated Dose-Escalation Data Demonstrate Clinical Activity in Heavily Pre-treated Patients Across Multiple Tumor Types
Plan to Initiate Expansion Evaluating SY-5609 in Combination with Chemotherapy in Pancreatic Cancer
48 Biggest Movers From Friday
Gainers
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.